BR112022025855A2 - Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo - Google Patents

Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo

Info

Publication number
BR112022025855A2
BR112022025855A2 BR112022025855A BR112022025855A BR112022025855A2 BR 112022025855 A2 BR112022025855 A2 BR 112022025855A2 BR 112022025855 A BR112022025855 A BR 112022025855A BR 112022025855 A BR112022025855 A BR 112022025855A BR 112022025855 A2 BR112022025855 A2 BR 112022025855A2
Authority
BR
Brazil
Prior art keywords
amine
vivo
nucleic acid
acid agents
polymers
Prior art date
Application number
BR112022025855A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark Saltzman W
Jiang Yuhang
Grun Molly
Suberi Alexandra
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of BR112022025855A2 publication Critical patent/BR112022025855A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/60—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from the reaction of a mixture of hydroxy carboxylic acids, polycarboxylic acids and polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6854—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/6856—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/916—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Polyamides (AREA)
BR112022025855A 2020-06-19 2021-05-27 Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo BR112022025855A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063041739P 2020-06-19 2020-06-19
PCT/US2021/034462 WO2021257262A1 (en) 2020-06-19 2021-05-27 Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery

Publications (1)

Publication Number Publication Date
BR112022025855A2 true BR112022025855A2 (pt) 2023-01-10

Family

ID=76859713

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025855A BR112022025855A2 (pt) 2020-06-19 2021-05-27 Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo

Country Status (10)

Country Link
US (1) US12558429B2 (https=)
EP (1) EP4168471A1 (https=)
JP (2) JP2023531444A (https=)
KR (1) KR20230042018A (https=)
CN (1) CN116157444A (https=)
AU (1) AU2021293780A1 (https=)
BR (1) BR112022025855A2 (https=)
CA (1) CA3183351A1 (https=)
MX (1) MX2022016581A (https=)
WO (1) WO2021257262A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
JP2024545093A (ja) * 2021-12-08 2024-12-05 イェール ユニバーシティー 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション
WO2023159189A1 (en) * 2022-02-18 2023-08-24 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
CN114874422B (zh) * 2022-06-16 2023-05-12 上海云沂生物医药科技有限公司 一种聚烷基胺、其合成方法、颗粒及用途
EP4324485A1 (en) * 2022-08-15 2024-02-21 Branca Banus Ltd A method for the production of pegylated hyperbranched poly( -amino ester)s, pegylated hyperbranched poly( -amino ester)s produced by those methods and their use in enhanced nucleic acid delivery
WO2024103225A1 (zh) * 2022-11-14 2024-05-23 林桂孜 一种阳离子聚酯及其制备方法和应用
EP4725977A1 (en) * 2023-06-08 2026-04-15 Integena Inc Efficient cationic polyester and use thereof
CN119490670A (zh) * 2024-11-26 2025-02-21 山东大学 一种慢病毒转染增强纳米颗粒及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415728A (en) 1979-11-08 1983-11-15 Her Majesty The Queen In Right Of Canada ε-Caprolactone co-polyesters useful for the preparation of polyurethane
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6849272B1 (en) 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
MXPA03000905A (es) 2000-08-02 2003-06-24 Slil Biomedical Corp Compuestos de poliamina ciclicos como tratamiento contra el cancer.
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US20030008000A1 (en) 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
EP1596875A4 (en) 2003-02-14 2006-04-05 Inolex Investment Corp TERTIARY AMINE FUNCTIONAL COMPLEX POLYESTER POLYMERS AND MANUFACTURING AND USE METHOD
KR100498971B1 (ko) 2003-04-04 2005-07-04 씨제이 주식회사 염색체 내 ｔｄｃＢＣ 및 ｐｃｋＡ 유전자가 불활성화된 미생물 및 이를 이용하여 Ｌ-쓰레오닌을 제조하는 방법
US20040242831A1 (en) 2003-05-30 2004-12-02 Dong Tian Enzyme catalyzed polyesters and polyol polymers
FR2873570B1 (fr) 2004-08-02 2007-01-05 Oreal Composition cosmetique de soin et/ou de maquillage comprenant au moins un polymere polyester amide
US8124128B2 (en) 2005-11-08 2012-02-28 Industrial Technology Research Institute Amphiphilic block copolymers and nano particles comprising the same
JP5277440B2 (ja) 2006-03-01 2013-08-28 国立大学法人 東京大学 核酸内包高分子ミセル複合体
WO2009114614A2 (en) 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9272043B2 (en) 2011-12-02 2016-03-01 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
US20210189062A1 (en) 2016-03-01 2021-06-24 Alexion Pharmaceuticals, Inc. Biodegradable activated polymers for therapeutic delivery
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US10874737B2 (en) 2018-06-01 2020-12-29 Iowa State University Research Foundation, Inc. Influenza nanovaccine
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
US11814464B2 (en) * 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US12162953B2 (en) 2019-12-06 2024-12-10 Yale University Enhanced targeting platform
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
MX2022009943A (es) 2020-02-14 2022-10-18 Etherna Immunotherapies Nv Vacunas intranasales de arnm.
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US20220031633A1 (en) 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023012824A1 (en) 2021-08-03 2023-02-09 Bharat Biotech International Limited Synergism of immunogenicity via combined parental and mucosal immunization against covid-19
JP2024545093A (ja) 2021-12-08 2024-12-05 イェール ユニバーシティー 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション

Also Published As

Publication number Publication date
WO2021257262A1 (en) 2021-12-23
MX2022016581A (es) 2023-02-01
KR20230042018A (ko) 2023-03-27
JP2026003134A (ja) 2026-01-09
EP4168471A1 (en) 2023-04-26
AU2021293780A1 (en) 2023-02-02
US20230233693A1 (en) 2023-07-27
JP2023531444A (ja) 2023-07-24
CA3183351A1 (en) 2021-12-23
US12558429B2 (en) 2026-02-24
CN116157444A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
BR112022025855A2 (pt) Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo
Robinson et al. Preparation and characterization of pH-responsive poly (methacrylic acid-g-ethylene glycol) nanospheres
Zhang et al. Rational design of anti‐inflammatory lipid nanoparticles for mRNA delivery
Lancina III et al. Chitosan nanofibers for transbuccal insulin delivery
Wu et al. Preparation, characterization, and release behavior of doxorubicin hydrochloride from dual cross-linked chitosan/alginate hydrogel beads
KR100314488B1 (ko) 다당류겔조성물
Ramachandran et al. Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery
Sun et al. Delivery of antipsychotics with nanoparticles
Franchini et al. Synthesis, physicochemical properties, and preliminary biological characterizations of a novel amphoteric agmatine-based poly (amidoamine) with RGD-like repeating units
CN100430093C (zh) 温度响应输送系统
CN101155844A (zh) 聚乙二醇-聚缩醛和聚乙二醇-聚缩醛-聚原酸酯接枝共聚物和药物组合物
Andrianov et al. Microneedles with intrinsic immunoadjuvant properties: microfabrication, protein stability, and modulated release
CN101869712B (zh) 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
Tan et al. Delivery of Anticancer Drugs Using Polymeric Micelles Stabilized by Hydrogen‐Bonding Urea Groups
Kaminski et al. Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists
Hsu et al. Structure‐Optimized Interpolymer Polyphosphazene Complexes for Effective Gene Delivery against Glioblastoma
EP2842548A1 (en) Polymeric synthetic antidote
Song et al. Multifunctional delivery nanosystems formed by degradable antibacterial poly (aspartic acid) derivatives for infected skin defect therapy
Kassick et al. Covalently loaded naloxone nanoparticles as a long-acting medical countermeasure to opioid poisoning
Nechaeva et al. The Synthesis and Properties of a New Carrier for Paclitaxel and Doxorubicin Based on the Amphiphilic Copolymer of N‐vinyl‐2‐pyrrolidone and Acrylic Acid
Acosta et al. Tramadol Release from a Delivery System Based on Alginate‐Chitosan Microcapsules
US7560444B2 (en) Polysaccharides for pulmonary delivery of active agents
Feng et al. Host− Guest Chemistry of Dendrimer− Drug Complexes. 5. Insights into the Design of Formulations for Noninvasive Delivery of Heparin Revealed by Isothermal Titration Calorimetry and NMR Studies
BR112023001379A2 (pt) Formulação de distribuição para distribuição seletiva a células imunes pulmonares, tais como macrófagos e monócitos, e método para tratar um indivíduo em necessidade da mesma
Junior et al. Impact of polyethylene glycol molar mass on physicochemical properties and protein interaction of chitosan-based nanoparticle

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements